GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (FRA:UR8) » Definitions » 3-Year FCF Growth Rate

UroGen Pharma (FRA:UR8) 3-Year FCF Growth Rate : 18.60% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma 3-Year FCF Growth Rate?

UroGen Pharma's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.88.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of UroGen Pharma was 18.60% per year. The lowest was -69.30% per year. And the median was -16.80% per year.


Competitive Comparison of UroGen Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, UroGen Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's 3-Year FCF Growth Rate falls into.



UroGen Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


UroGen Pharma  (FRA:UR8) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


UroGen Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma (FRA:UR8) Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

UroGen Pharma (FRA:UR8) Headlines

No Headlines